Publications
Detailed Information
Oncologic safety of gonadotropin-releasing hormone agonist for ovarian function protection during breast cancer chemotherapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hee Jeong | - |
dc.contributor.author | Lee, Moo Hyun | - |
dc.contributor.author | Lee, Jeong Eon | - |
dc.contributor.author | Park, Seho | - |
dc.contributor.author | Lee, Eun Sook | - |
dc.contributor.author | Kang, Yong Joon | - |
dc.contributor.author | Shin, Hae Na | - |
dc.contributor.author | Kim, Seung Il | - |
dc.contributor.author | Lee, Jun Ho | - |
dc.contributor.author | Im, Seock Ah | - |
dc.contributor.author | Ahn, Sei Hyun | - |
dc.contributor.author | Lee, Keun Seok | - |
dc.contributor.author | Sohn, Joohyuk | - |
dc.contributor.author | Kim, Seonok | - |
dc.contributor.author | Nam, Seok Jin | - |
dc.contributor.author | Han, Wonshik | - |
dc.date.accessioned | 2022-03-22T09:24:06Z | - |
dc.date.available | 2022-03-22T09:24:06Z | - |
dc.date.created | 2019-06-24 | - |
dc.date.created | 2019-06-24 | - |
dc.date.created | 2019-06-24 | - |
dc.date.created | 2019-06-24 | - |
dc.date.issued | 2018-10 | - |
dc.identifier.citation | Clinical Breast Cancer, Vol.18 No.5, pp.e1165-e1172 | - |
dc.identifier.issn | 1526-8209 | - |
dc.identifier.other | 76494 | - |
dc.identifier.uri | https://hdl.handle.net/10371/177313 | - |
dc.description.abstract | Chemotherapy with a gonadotropin-releasing hormone (GnRH) agonist has been reported to protect against ovarian failure. This retrospective, individual matching study from 5 large institutes in Korea found that disease-free survival and distant metastasis-free survival were better in a GnRH agonist group than in a chemotherapy-alone group. Background: Receipt of a gonadotropin-releasing hormone (GnRH) agonist has been reported to protect against ovarian failure. We sought to determine the oncologic effect of a GnRH agonist with chemotherapy for breast cancer patients. Patients and Methods: Data from 1160 patients aged 20 to 40 years with stage I to III breast cancer who received chemotherapy from 5 hospitals in Korea from 2002 to 2012 were reviewed. A GnRH agonist was provided to 406 patients for ovarian protection during chemotherapy, and 754 patients received chemotherapy without ovarian protection. An individual score-matching strategy was used to create sets matched by age, tumor stage, hormone receptor status, neoadjuvant or adjuvant chemotherapy, and institute. Results: Survival analysis by Cox regression showed that the GnRH agonist group had better distant metastasis-free survival (hazard ratio [HR], 0.59; 95% confidence interval [CI], 0.39-0.89) and disease-free survival (HR, 0.72; 95% CI, 0.52-0.99) than the chemotherapy-alone group. Among patients with hormone receptor-positive breast cancer, the benefit was significant for distant metastasis-free survival (HR, 0.53; 95% CI, 0.29-0.99) and disease-free survival (HR, 0.58; 95% CI, 0.35-0.96). Conclusion: Ovarian protection using a GnRH agonist can be safely considered for premenopausal breast cancer patients for whom chemotherapy is planned. | - |
dc.language | 영어 | - |
dc.publisher | Cancer Information Group | - |
dc.title | Oncologic safety of gonadotropin-releasing hormone agonist for ovarian function protection during breast cancer chemotherapy | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1016/j.clbc.2018.04.008 | - |
dc.citation.journaltitle | Clinical Breast Cancer | - |
dc.identifier.wosid | 000445702400056 | - |
dc.identifier.scopusid | 2-s2.0-85047392704 | - |
dc.citation.endpage | e1172 | - |
dc.citation.number | 5 | - |
dc.citation.startpage | e1165 | - |
dc.citation.volume | 18 | - |
dc.identifier.sci | 000445702400056 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Im, Seock Ah | - |
dc.contributor.affiliatedAuthor | Han, Wonshik | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | ADJUVANT CHEMOTHERAPY | - |
dc.subject.keywordPlus | FERTILITY PRESERVATION | - |
dc.subject.keywordPlus | YOUNG-WOMEN | - |
dc.subject.keywordPlus | GNRH AGONIST | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | SUPPRESSION | - |
dc.subject.keywordPlus | AMENORRHEA | - |
dc.subject.keywordPlus | RECOMMENDATIONS | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | CONSENSUS | - |
dc.subject.keywordAuthor | Breast cancer | - |
dc.subject.keywordAuthor | Chemotherapy | - |
dc.subject.keywordAuthor | Fertility | - |
dc.subject.keywordAuthor | Ovarian suppression | - |
dc.subject.keywordAuthor | Premenopausal | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.